Autonomix Medical Reports Increased Net Losses and Rising Operating Expenses for Six Months Ended September 30, 2025

Autonomix Medical, Inc. reported significant financial results for the three and six months ended September 30, 2025, reflecting a net loss of $7.5 million and $10.8 million, respectively. This marks an increase from the net losses of $2.8 million and $5.5 million reported for the same periods in 2024. The company did not generate any revenue during these periods, maintaining an accumulated deficit of $61.2 million as of September 30, 2025. Total operating expenses surged to $7.5 million for the three months and $10.9 million for the six months, compared to $2.8 million and $5.6 million in the prior year, primarily driven by increased research and development costs and general administrative expenses.

The company's operational metrics indicate a substantial rise in expenses, with research and development costs increasing by 102% to $2.4 million for the three months ended September 30, 2025, and by 86% to $4.0 million for the six months. General and administrative expenses also saw a significant rise, up 211% to $5.2 million for the three months and 102% to $7.0 million for the six months, largely due to stock-based compensation and increased legal and professional fees. The company’s cash position decreased to $7.5 million from $9.1 million at the end of the previous fiscal period, with working capital reported at $6.4 million.

Strategically, Autonomix has made notable advancements in its product development and clinical trials. The company completed its first-in-human proof-of-concept study for its catheter-based solution targeting pain associated with pancreatic cancer, which yielded positive outcomes. Following this, a follow-on study was initiated to expand the protocol to include additional cancer types. The company also strengthened its intellectual property portfolio with the issuance of new patents and presented its technology at major medical conferences.

In terms of financing, Autonomix entered into a Purchase Agreement with Lincoln Park Capital Fund, allowing for the potential sale of up to $15 million in common stock. As of September 30, 2025, the company had sold 1,682,685 shares under this agreement, generating approximately $2.5 million in net proceeds. The company also engaged in warrant inducement agreements, resulting in gross proceeds of approximately $2.5 million. However, management has indicated that additional capital will be necessary to fund operations and advance its business plan, estimating a need for $30 to $36 million to reach commercialization of its first indication.

Looking ahead, Autonomix acknowledges the challenges it faces in securing additional financing and achieving regulatory approvals for its products. The company’s current cash resources are projected to sustain operations only into the third calendar quarter of 2026, emphasizing the urgency of raising further capital. The management has expressed that failure to secure sufficient funding could necessitate scaling back operations, which would adversely affect its ability to meet financial obligations and achieve business objectives.